Berhan Ayenew, Bayleyegn Biruk, Getaneh Zegeye
Department of Medical Laboratory Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Blood Lymphat Cancer. 2022 Apr 29;12:31-45. doi: 10.2147/BLCTT.S361320. eCollection 2022.
Lymphoma is one of the hematologic malignancies that occur at a higher rate in human immunodeficiency virus-infected individuals. It is one of the most frequent neoplastic causes of death in those individuals. Non-Hodgkin's lymphoma and Hodgkin's lymphomas are acquired immunodeficiency syndrome defining lymphoma and non-acquired immunodeficiency syndrome defining lymphoma, respectively. Non-Hodgkin's lymphoma is the most common type of lymphoma in human immunodeficiency virus-positive people. The lymphoma that develops in patients infected with the human immunodeficiency virus/acquired immunodeficiency syndrome is heterogeneous in terms of morphology, pathogenesis pathways, and cellular derivation. A narrative review was conducted on the basis of relevant literature on the current topic to summarize the current epidemiology, pathogenesis, laboratory diagnosis, and treatment of lymphoma in human immunodeficiency virus-infected patients. The finding showed that although the incidence of non-Hodgkin's lymphoma has decreased after the advent of highly active antiretroviral therapy, it has remained higher in human immunodeficiency virus-infected people than in the general population. On the other hand, the incidence of Hodgkin's lymphoma has increased after the introduction of highly active antiretroviral therapy. Therefore, it is recommended that people living with human immunodeficiency virus/ acquired immunodeficiency syndrome be screened for the development of lymphoma to increase their survival time and quality of life, and further research is required regarding the pathogenesis, treatment, and laboratory diagnosis of human immunodeficiency virus/ acquired immunodeficiency syndrome-associated lymphoma.
淋巴瘤是血液系统恶性肿瘤之一,在感染人类免疫缺陷病毒的个体中发病率较高。它是这些个体中最常见的肿瘤致死原因之一。非霍奇金淋巴瘤和霍奇金淋巴瘤分别是获得性免疫缺陷综合征定义的淋巴瘤和非获得性免疫缺陷综合征定义的淋巴瘤。非霍奇金淋巴瘤是人类免疫缺陷病毒阳性人群中最常见的淋巴瘤类型。感染人类免疫缺陷病毒/获得性免疫缺陷综合征的患者所患的淋巴瘤在形态学、发病机制途径和细胞来源方面具有异质性。基于当前主题的相关文献进行了叙述性综述,以总结人类免疫缺陷病毒感染患者淋巴瘤的当前流行病学、发病机制、实验室诊断和治疗。研究结果表明,尽管高效抗逆转录病毒疗法出现后非霍奇金淋巴瘤的发病率有所下降,但在感染人类免疫缺陷病毒的人群中仍高于普通人群。另一方面,高效抗逆转录病毒疗法引入后霍奇金淋巴瘤的发病率有所上升。因此,建议对感染人类免疫缺陷病毒/获得性免疫缺陷综合征的人群进行淋巴瘤筛查,以提高他们的生存时间和生活质量,并且需要进一步研究人类免疫缺陷病毒/获得性免疫缺陷综合征相关淋巴瘤的发病机制、治疗和实验室诊断。